Loncastuximab Tesirine

CHEMBL4297778 Phase 4 Approuvé Antibody drug conjugate
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

An antibody-drug conjugate targeting CD19 on malignant B cells, used to treat relapsed or refractory diffuse large B-cell lymphoma and leukemia. It delivers a cytotoxic agent directly to cancer cells while sparing most normal tissues.

Aires thérapeutiques

Mécanisme d'action

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

An antibody-drug conjugate targeting CD19 on malignant B cells, used to treat relapsed or refractory diffuse large B-cell lymphoma and leukemia. It delivers a cytotoxic agent directly to cancer cells while sparing most normal tissues.

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Yes, Loncastuximab Tesirine is an approved drug. It has reached clinical phase 4. It is classified as a Antibody drug conjugate.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297778. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.